Type 2 diabetes is the most prevalent cause of chronic kidney disease (CKD) that may progress to end-stage renal disease (dialysis and/or transplant) Diabetic nephropathy is the most likely cause of CKD especially associated with suboptimal glycemic control.
Kidney function is categorized, based on estimated glomerular filtration rate (eGFR), (1) .
as: normal; mild; moderate; severe; end-stage. Stage (2). In the UKPDS, 28% of patients with type 2 diabetes developed renal impairment after a median of 15 years after diagnosis of diabetes (3) . Impaired renal function is associated with increased cardiovascular risk which is further increased by poor glycemic control (1, 4) .
Effective treatment of patients with type 2 diabetes and moderate renal impairment is challenging. Pharmacokinetic aspects of drugs cleared by the kidney can be influenced by renal impairment leading to the cessation or dosage reduction in many glucoselowering therapies (5) (6) (7) (8) that may have reduced tolerability or increased safety risk in this population (9) (10) (11) (12) .
Liraglutide, a once-daily human GLP-1 analog (13) , is completely metabolized through a proteolytic mechanism and is not predominantly eliminated by a single organ (14) . A single-dose (0.75 mg subcutaneously) pharmacokinetic trial with liraglutide provided initial evidence that the exposure to liraglutide was not increased in patients with all stages of renal impairment relative to patients with normal renal function (15) . A metaanalysis from the six Liraglutide Effect and Action in Diabetes (LEAD) trials has shown that the glycemic efficacy and safety of liraglutide (1.2 mg or 1.8 mg) in patients with mild renal impairment (eGFR 60-89 mL/min/1.73m 2 ) was similar to those with normal renal function (16) .
The primary objective of this trial was to demonstrate the superiority of liraglutide 1.8 mg versus placebo as add-on to existing oral glucose-lowering agents and/or insulin therapy on glycemic control after 26 weeks' treatment in patients with type 2 diabetes and moderate renal impairment (Stage 3 CKD) (Clinicaltrials.gov registry number: NCT01620489).
Methods

Trial Design
This trial was conducted in order to provide efficacy and safety data in a population with moderate renal impairment and to update the label with this information. This 26-week randomized, double-blind, placebo-controlled, parallel-group trial was conducted between June 2012 and August 2013 and included patients from 78 sites: France (4 sites), Poland (8) , Russian Federation (15), Ukraine (6) , UK (9) , USA (36) .
Trial patients who met the eligibility criteria at screening were randomized (1:1), using a sponsor-provided telephone-or web-based randomization system, to receive once-daily subcutaneously-administered liraglutide or placebo. Trial site personnel, patients and sponsor remained blinded until trial completion. Stratification was based on the assessment of renal function (eGFR <45 or >45 mL/min/1.73m 2 [Modification of diet in renal disease formula; MDRD]) using standardized creatinine measurements and insulin treatment (basal, premix or no insulin). Liraglutide or placebo were initiated with a starting dose of 0.6 mg/day, with subsequent weekly dose-escalations of 0.6 mg/day until the maintenance dose of 1.8 mg/day was reached (Supplemental Figure S1 ). At the discretion of the investigator, the dose escalation could have been extended up to 4 weeks in case of gastrointestinal side-effects. Treatment was continued for a total of 26 weeks with a 1-week follow-up period. For patients using insulin with an HbA 1c <8% (64 mmol/mol) at screening, the pre-trial insulin dose was reduced by 20% at Day 0 and kept fixed until the liraglutide dose escalation was complete. Titration to the pre-trial insulin dose was allowed at the discretion of the investigator. Patients were to maintain their background diabetes medication throughout the trial. Patients using either insulin or a sulfonylurea (SU) were allowed to reduce the dose of these agents if hypoglycemic episodes occurred. The protocol was reviewed and approved by the appropriate independent ethics committees or institutional review boards. All patients provided written informed consent prior to the commencement of any trial related activities.
Trial Population
Assessments
The primary efficacy endpoint was the change in HbA 1c from baseline to Week 26. 
Results
Patient Disposition
In total, 279 patients were randomized to receive either liraglutide 1.8 mg or placebo (140 and 139 patients, respectively) (Supplemental Figure S2) . Two patients in the placebo group were not exposed to trial medication. . All remaining patients exposed to either liraglutide (140) or placebo (137) were included in the analysis sets.
Approximately 25% of patients in each group withdrew from the trial. More patients in the liraglutide group withdrew due to AEs (19; 13.6%) than in the placebo group (4; 2.9%).
Demographics and Baseline Characteristics
Patient demographics and baseline characteristics were generally well-balanced between the two treatment groups ( Both treatment groups exhibited a gradual weight reduction during the trial ( Figure 1D ).
The patients in the liraglutide group had a greater reduction in body weight than the placebo group (-2.41 kg and -1.09 kg, respectively) with an ETD of - The total daily insulin dose at week 26 decreased by 8% in the liraglutide group and by 3% in the placebo group. The changes in the dose of sulfonylureas were not determined.
From baseline to Week 26, there was no treatment difference observed for change in the fasting lipid profile (P-value range 0.21 to 0.81) (Supplementary Table S2 ).
Several biomarkers were evaluated in order to assess the cardiovascular effects of liraglutide (Supplementary Table S3 ).
SBP reduction occurred in both treatment groups (-2.45 mmHg with liraglutide; -0.33 mmHg with placebo) but there was no difference between treatments (P=0.25). There was no difference between treatments in DBP (P=0.89).
Safety
Over the 26-week trial period, the overall incidence of AEs and serious AEs (SAE) was comparable between the two treatment groups ( Table 2 ). The patients recovered from the AE/SAE with equal frequency between both treatment groups. A post-hoc analysis based on eGFR subgroup indicated that there was no difference in the percentage of subjects treated with liragutide who reported AEs (75.9% and 77.0% for Stage 3A and
Stage 3B CKD, respectively; Supplementary Table 5) . (21) The most common AEs reported with liraglutide were gastrointestinal (35.7%), which tended to resolve quickly, and the majority were considered mild in severity. However, for subjects in the liraglutide group who withdrew due to a GIAE (9 subjects; 11 events), the majority of AEs were either moderate (6 events) or severe (4 events Table S4 ). The deaths were not clustered within a specific system organ class or eGFR stratum (liraglutide: 2 subjects Stage 3A stratum; 2 subjects Stage 3B stratum; placebo: Stage 3B stratum). The relationship to trial product was assessed by the investigator as unlikely for the four liraglutide cases and as possible for the placebo case.
In the liraglutide group 20.7% of patients (97 episodes) and in the placebo group 26.3% (160 episodes) experienced documented symptomatic hypoglycemic episodes (20) (Figure 2A and severe (7.3%) renal impairment (eGFR >15 to <90 mL/min/1.73m
2 ) (23) demonstrated that once-weekly albiglutide was more efficacious than sitagliptin. Like liraglutide, albiglutide is degraded by enzymatic catabolism (23) whereas exenatide (24) and lixisenatide (25) although not statistically significant. Albuminuria is not only a marker for kidney damage but it is also a cardiovascular risk factor (33, 34) .
Patients with chronic kidney disease and diabetes are at increased risk of hypoglycemia, particularly when using insulin (35) . A smaller percentage of patients treated with liraglutide experienced a hypoglycemic episode than those treated with placebo. There was a comparable risk in the event rate of hypoglycemia between both groups. Considering that more than half of the patients were treated with insulin, this supports that liraglutide does not increase the hypoglycemia risk in this population.
Volume depletion events, such as nausea, vomiting and diarrhea, in patients with CKD, could, potentially, adversely affect kidney function (1). Even though more patients treated with liraglutide reported these types of events in this trial, most were mild in intensity and resolved quickly. There was one severe case of nausea and two of vomiting reported in the liraglutide group. In the LEAD 1-5 trials, the incidence of nausea, diarrhea and vomiting ranged from 6.8-40%, 7.9-18.7%, and 5-17%, respectively (26) (27) (28) (29) (30) (31) (32) The placebo-controlled design of this trial is another limitation. However, liraglutide was investigated as an add-on to a wide array of glucose-lowering medications including
insulin. As such, we believe that placebo was the most appropriate comparator.
An additional limitation for this trial is that stratification by eGFR was based on results at the screening visit even though eGFR was also assessed at the randomization visit. It is acknowledged that serum creatinine levels may have varied between the visits.
Nonetheless, this would be as likely in both the liraglutide and the placebo groups and therefore, should not bias the results of the trial.
Liraglutide did not affect renal function, demonstrated better glycemic control and weight reduction with no increase in hypoglycemia risk but with higher withdrawals due to GI adverse events than placebo in patients with type 2 diabetes and moderate renal impairment.
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Workup to Assess Possible Cases of Pancreatitis
The investigator was to ensure that subjects were informed of the characteristic symptoms of acute pancreatitis as part of the informed consent process. Confirmed cases of pancreatitis were to be followed-up with investigations of other potential causes (tests such as gallbladder ultrasound, triglycerides, liver enzymes, detailed history of concomitant medications or alcohol were suggested for follow up as part of the Investigators considerations relative to local standards of practice). If the investigator suspected acute pancreatitis, all suspected drugs were to be discontinued until confirmatory tests were conducted and appropriate treatment initiated. Subjects diagnoses with acute pancreatitis (as a minimum 2 of 3: characteristic abdominal pain, amylase and/or lipase >3UNR or characteristic findings on CT scan /MRI) were to be withdrawn from the study. 0.7132 LOCF, last observation carried forward; SD, standard deviation; LDL, low density lipoprotein; VLDL, very low density lipoprotein; HDL, high density lipoprotein; *estimated treatment ratio=estimated ratio to baseline for liraglutide/estimated ratio to baseline for placebo (statistical analysis performed on log scale). 
Protocol Amendments
There were 1 global and 7 local substantial protocol amendments to the final protocol (dated 09-April-2013). Protocol amendments were approved according to local requirements prior to implementation.  Update to Protocol Section 17 Statistical Considerations. Based on consistent FDA feedback on use of LOCF in clinical trials in general, the statistical analyses section had been revised so that the primary statistical analysis will be performed using a mixed model for repeated measurements (MMRM), whereas ANCOVA using LOCF will be performed as described as a sensitivity analysis.
 General administrative and editorial updates. In addition, a few minor inconsistencies were discovered which were corrected to ensure correct interpretation of the trial protocol. This included an update of Appendix B.
 Update of master subject information/informed consent (SI/IC) and introduction of an additional SI/IC for subjects with confirmed C-cell abnormality. The master SI/IC was updated to reflect the possibility of genetic testing in case of thyroid surgery during the trial and an additional SI/IC was introduced to be obtained only from subjects with confirmed C-cell abnormality.
The remaining 5 local substantial amendments allowed for opening of new sites.
